

From: [REDACTED]
Sent: Wednesday 13 January 2021 23:28
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER
Attachments: Full EC Tender Sante-2020-C3-087 w signed APA cover letter.pdf; Annex 1 - Secretary's Certificate .pdf

Categories: Treated - to file, [REDACTED]

Dear [REDACTED],

In response to your message from this morning – note the question highlighted in #2 & #3:

1. Thank you for your response – we are considering the economic capacity request by SANTE-PROCUREMENT fulfilled.
2. **For the identified subcontractors: we would ask you to provide the Evidence that the person(s) [REDACTED] of the entity (see Section 4.3 of the Tender Specifications). Please note that [REDACTED] the two documents are [REDACTED].**

3. **We would also ask you to resubmit the document “Novavax European Commission Tender - SANTE-2020-C3-087” [REDACTED]**

Regards,


Creating Tomorrow's Vaccines Today

21 Firstfield Road
Gaithersburg, MD 20878
Direct Line: [REDACTED]
Mobile: [REDACTED]
Email: [REDACTED]
www.novavax.com

From: [REDACTED]
Sent: Wednesday, January 13, 2021 9:06 AM
To: [REDACTED] >
Cc: [REDACTED]
Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

[REDACTED]
Dear [REDACTED],

Please find below further clarifications and requests regarding your tender:

1. Evidence regarding the financial and economic capacity [REDACTED]
Tender Specifications – we confirm that the information provided by you with the tender is [REDACTED]
2. For the identified subcontractors: we would ask you to provide the Evidence that the person(s) [REDACTED] of the entity (see Section 4.3 of the Tender Specifications). Please note that [REDACTED] the two documents are [REDACTED].
3. We would also ask you to resubmit the document “Novavax European Commission Tender - SANTE-2020-C3-087” [REDACTED]

We remain at your disposal in case of any questions and doubts.

Kind regards



European Commission
DG Health and Food Safety

From: [REDACTED]
Sent: Monday, January 11, 2021 1:35 PM
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Thank you for the response. We look forward to hearing back.
Regards,

From: [REDACTED]
Sent: Monday, January 11, 2021 3:10 AM

To: [REDACTED]
Cc: [REDACTED]
Subject: RE: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

[REDACTED]

Dear [REDACTED],
We confirm the receipt of the documents, we will review them and come back to you with further requests if necessary.
Regarding your question about the additional financial documents, we need further consultation in that matter and we will come back to you with a clarification.

Kind regards

[REDACTED]



European Commission
DG Health and Food Safety

[REDACTED]

From: [REDACTED] >
Sent: Friday, January 8, 2021 4:21 PM
To: [REDACTED] >
Cc: [REDACTED]
Subject: Fwd: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED],
Please see the following email with attachments as follow up to your recent request. We look forward to any updates.

Kind Regards,
[REDACTED]
Novavax, INC.
Get [Outlook for iOS](#)

From: [REDACTED]
Sent: Friday, January 8, 2021 10:12 AM
To: [REDACTED]
Cc: [REDACTED]
Subject: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED],

In response to the additional information you requested on [REDACTED], we are providing the following in hopes that it meets your needs:

1. [REDACTED]

2a. Evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications

1. [REDACTED]

2b. Evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

2. [REDACTED]

Confidentiality Note

Please be advised that Novavax, Inc. (together with its subsidiaries "Novavax") is providing this proposal solely for the European Commission ("EC") to use in the call for tenders SANTE/2020/C3/087 - for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States (the "Project") and with the understanding that proposal contents will be treated as confidential. The information included in this proposal is confidential and/or private internal information of Novavax and its suppliers that is commercially sensitive and valuable. In accordance with the EC's procedures and relevant European Union law, we hereby request confidential treatment of all of the materials included in the proposal

Cheers,



22 Firstfield Road
Gaithersburg, MD 20878
Mobile: [REDACTED]
Email: [REDACTED]
www.novavax.com

From: [REDACTED]
Sent: Wednesday, January 6, 2021 10:41 AM
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED]

After a first review of the documents submitted by Novavax Inc. it seems that we are missing the following elements:

1. Evidence regarding the financial and economic capacity F1 [REDACTED] as described in **section 3.2.2. of the Tender Specifications.**
2. Evidence regarding the exclusion criteria as described in the section **VI of the** [REDACTED]
 1. **As evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications:** [REDACTED]
 2. **As evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:** [REDACTED]

Please note that this is a first, general review of your submission, and we might come back to you with further requests following the assessment by the evaluation committee.

We remain at your disposal in case of any doubts or questions regarding the request.

Kind regards



European Commission

DG Health and Food Safety

